CEO and Board Member
With over 30 years of pharma/biotech experience, Mr. McCullough is a demonstrated strategic, creative, and accomplished leader. With executive and board director experience in startup and established companies, David brings expertise in both the private and public sector. He has a deep understanding of drug development, clinical and regulatory strategy, commercial, finance, IP, manufacturing and operations. Mr. McCullough has a proven track record of building highly skilled, energetic, cross-functional teams both domestically and globally. He has strong experience moving products from early development to launch, including orphan drugs and billion-dollar brands. At Merck, he played a lead role in the $13.5B acquisition of Serono Biotech, and he was honored by the Merck family as a top contributor in corporate development. Additionally, Mr. McCullough has held leadership positions in Allergopharma/EMD Serono and BioCryst. He is interested in Enterin as he has a personal passion for the neurodegenerative therapeutic area and the patient population that can be served with better therapeutic outcomes.
Chief Financial Officer
Ms. Wolf brings 30 years of health care industry experience in capital raising, business development, and strategy, during which she has executed financing, advisory, and M&A transactions worth approximately $24 billion. She has deep experience as a healthcare CFO, advisor, and investment banker. Her background in capital markets, her reputation among the financial community, and her experience as a public company CFO will help Enterin position the company for the the next phase of growth.
Before joining Enterin, Ms. Wolf was Managing Member of health care consultancy KLW Advisors where she worked as an advisor and Acting CFO to various clients, prior to which she served as Partner and Senior Advisor at Ondra Partners, a boutique investment bank. Previously, her positions included CEO & Co-Founder of health care consultancy Rocket Science, and CFO & EVP of Vision-Sciences, a publicly traded medical technology company. Additionally, Ms. Wolf has extensive prior health care investment banking experience at both global and boutique investment banks, including HSBC Securities, Bear Stearns and SG Cowen. Ms. Wolf received an MBA from Harvard Business School and a BA from Williams College.
Richard Larson, MD, PhD
Chief Medical Officer
Richard S. Larson MD, PhD has 35+ years experience in bioscience and healthcare industries. He is a physician-scientist, inventor, professor, health care leader, and entrepreneur. Dr. Larson founded and served as the director of the Clinical and Translational Science Center in New Mexico for 17 years, an organization that runs 60-250 clinical trials annually.
Dr. Larson is also an accomplished inventor and entrepreneur. His scientific achievements include more than 100 peer-reviewed publications and over 40 patents. Several patents served as the basis for new biotechnology companies in the areas of drug development, radioimaging, and in vitro diagnostics. His inventions have been recognized with the Chief Scientist Award for Excellence from the Defense Intelligence Agency and a Top 100 Technology Award from R&D Magazine. He is an honorary commander at Kirkland Air Force base.
Dr. Larson helped launch, lead, and govern TriCore Reference Laboratories, which has grown into one of New Mexico’s 9th largest businesses. In addition, having served as Executive Vice Chancellor and Vice President for Research of a $2.4 billion health care entity for more than 10 years, he has overseen a broad array of activities and programs in education, research, community outreach and clinical care. He also serves on the board of directors of Triopsy, Inc, a company developing devices and AI to improve biopsy techniques and the diagnosis of prostate cancer.
Dr. Larson received both his M.D. and Ph.D. from Harvard University. He completed his residency at Washington University in St. Louis and his fellowship training at Vanderbilt University.
William Kinney, PhD
Co-Founder, Senior VP, Research & Development
Dr. Kinney is a drug discovery scientist, process development chemist, and entrepreneur with greater than 30 years of experience in large pharmaceutical (Wyeth, Johnson & Johnson), biotechnology (Magainin), and non-profit (Blumberg Institute) research and development.
He has demonstrated expertise in drug design; synthesis; lead optimization of peptides, small molecules, natural products, and cGMP drug development; and is inventor of three molecules that advanced to human clinical trials – Perzinfotel (CNS disorders and pain), Squalamine (oncology and AMD), and Trodusquemine (obesity). He was the chemistry leader on the initial squalamine IND project team, delivering drug substance to launch a Phase I clinical trial on time and on budget. The squalamine cGMP scale-up campaign required building and leading an internal process group, partnering with analytical chemistry on method development and stability studies, working with multiple domestic and international collaborators, and writing the CMC section of the IND.
In 2000, he joined Johnson & Johnson, where he pursued peptide-mimetic integrin antagonists and urotensin-II receptor modulators for cardiovascular indications. He also made seminal discoveries with respect to self-assembling collagen-mimetic peptides that stimulate platelet aggregation.
Currently, Dr. Kinney is co-founder and Vice President of Research and Development at Enterin, Inc. where he leads scale-up of drug substance and drug product for the ENT-01 IND for the treatment of Parkinson’s Disease. His scientific contributions include 80 publications, invited lectures, and oral presentations and inventorship on 42 issued U.S. patents.
Senior Regulatory Advisor, Regulatory Strategy and Operations
With over 30 years’ in the biotechnology/pharmaceutical industry, Hilde is an expert in strategic regulatory affairs and clinical development across multiple disease areas and compound classes. Hilde’s deep regulatory affairs expertise has focused on investigational pharmaceutical products, including Phase I through Phase IV development. Hilde served as Sr. Vice President, Regulatory Affairs and Development, Acadia Pharmaceuticals where she oversaw the only successful Phase 3 program in Parkinson’s Disease Psychosis. Hilde garnered FDA agreement for an NDA submission based on a single study, gained strategic Breakthrough Designation (first for FDA Psychiatry Division) and oversaw development of a high-quality NDA granted Priority Review by the FDA, and subsequent approval. During her career, Hilde has provided leadership on regulatory and development activities associated with the launch and conduct of five other development programs for CNS and psychiatric indications.